After blocking the effect of inflammasome activation by administration of YVAD‐CMK in vivo, the levels of capase‐1 and IL‐1β remarkably were reduced in tumour from Ad‐CAIXpromotor‐AIM2 group than Ad‐CAIXpromotor group (Figure 5A,B). This evidence concerns the gene AIM2 and neoplasm.